Abstract
Objectives: Sacubitril/valsartan has shown benefits in managing heart failure with reduced ejection fraction (HFrEF). However, more data on its effectiveness and safety in diverse populations is needed. This study evaluated its long-term effects on echocardiographic and clinical parameters of heart function and reverse cardiac remodeling in Omani patients with HFrEF, with an emphasis on gender-related differences. Methods: This retrospective cohort study was conducted at a tertiary hospital in Oman from January 2018 to December 2023. Data were collected through retrospective chart reviews and follow-up assessments conducted 12 months after initial assessment. Results: Among the patients, 72.5% were male, with a mean age of 60.1 ± 11.4 years. Significant improvements were observed in systolic blood pressure (137.7 ± 19.38 to 131.59 ± 19.23 mmHg, p = 0.013), diastolic blood pressure (80 to 74.5 mmHg, p < 0.001), heart failure class (2 to 1, p < 0.001), left ventricular ejection fraction (31% to 37%, p < 0.001), end-systolic volume (112.69 ± 37.78 mL, p = 0.011), and left atrium diameter (4.1 to 4 cm, p = 0.002). Female patients experienced greater treatment benefits. No association was found between reverse cardiac remodeling and gender or comorbidities. Conclusion: Sacubitril/valsartan demonstrated significant benefits in managing HFrEF in Omani patients. Gender differences in response highlight the need for personalized treatment strategies.

This publication has 1 reference indexed in Scilit: